- April 27, 2007
Scientists have identified three new stretches of DNA that appear to boost the chance of getting diabetes.
A series of papers report three genetic regions that each boost the risk of the disease by roughly 10% to 40%.
Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels
Abstract at
Science;
full text at
Science, requires subscription;
PDF file.
A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants
Science DOI: 10.1126/science.1142382
Abstract at
Science;
full text at
Science, requires subscription;
PDF file.
Replication of Genome-Wide Association Signals in U.K. Samples Reveals Risk Loci for Type 2 Diabetes
Science DOI: 10.1126/science.1142364
Abstract at
Science;
full text at
Science, requires subscription;
PDF file.
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
Nature Genetics doi:10.1038/ng2043.
Letter abstract at
Nature Genetics.
[Story at ScienceNOW:
Genomic Hunt Captures "Diabetes DNA".]
Advertisement
|
Advertisement
|
- April 24, 2007
Jenna Scarsi is the newest winner of the Bayer Dream Fund, an
annual contest for people with diabetes who want to achieve a special dream
that might not have been possible unless they
were in control of their diabetes. Through
this award, Scarsi, age 30, will be able to tour the
country with a grassroots program she created called Lights, Camera, Cure to increase
diabetes awareness and education and to empower young people with diabetes.
[Press release at EARTHtimes.org:
Bayer Diabetes Care Announces Winner of $100,000 4th Annual Bayer Dream Fund(TM) Contest.]
- April 14, 2007
Scientists have developed a promising new therapy that targets the progression of
type 2 diabetes, the most common
form of the disease.
In the study, they found that daily injections of anakinra — a drug also used to treat rheumatoid arthritis — helped patients by targeting a cause of the disease.
Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus
NEJM
Volume 356:1517-1526, Number 15. April 12, 2007
[Story at People's Daily Online:
Abstract at
NEJM;
full text at
NEJM, requires subscription.]
- April 7, 2007
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) approved
JANUMET™, the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor,
sitagliptin
(also known as JANUVIA™), and
metformin
for the treatment of
type 2 diabetes.
[Press release at Merck:
FDA Approves JANUMET™ for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet.]
- April 1, 2007
Editors of several leading scientific journals announced today that they are resigning, and their journals are being discontinued, now that world-reknown scientists are posting the results of their studies on their own blogs.
[Story at the
Diabetes Monitor:
Blogs replace scientific journals.]
|
|
|
